Literature DB >> 32400905

Cannabidiol on 5-FU-induced oral mucositis in mice.

Letícia de Freitas Cuba1,2, Fernanda Gonçalves Salum1, Francisco Silveira Guimarães3, Karen Cherubini1, Ruchielli Loureiro Borghetti4, Maria Antonia Zancanaro de Figueiredo1.   

Abstract

PURPOSE: The aim of this study was to evaluate the clinical, histological, hematological, and oxidative stress effects of cannabidiol (CBD) in mice with induced oral mucositis.
METHODS: We used 90 mice of the CF-1 strain in which oral mucositis was induced using a protocol with 5-fluorouracil (5-FU) chemotherapy. The animals were divided randomly into 10 study groups. Three groups were treated with different doses of CBD (3, 10, and 30 mg/kg), while 2 were control groups (positive control: 5-FU + mechanical trauma + placebo; and negative control: mechanical trauma + placebo), and 2 experimental times were studied (4 and 7 days). All treatments were by intraperitoneal administration.
RESULTS: In the clinical evaluation, the groups treated with CBD showed less severity of oral lesions compared with the positive control at both experimental times. The intensity of the inflammatory response was also lower in the groups treated with this drug, but there was no statistically significant difference when compared with the positive control. With regard to erythrocyte, leukocyte, and platelet counts and anti-oxidant enzyme activity, the groups treated with CBD showed better results, but only some of these variables showed statistically significant differences.
CONCLUSIONS: CBD seems to exert an anti-inflammatory and anti-oxidant activity favoring a faster resolution of oral mucositis in this animal model.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. All rights reserved.

Entities:  

Keywords:  5-FU chemotherapy; CAT; GSH; anti-oxidant enzymes; cannabidiol; erythrocyte count; inflammatory score; mice; mucositis classification; oral mucositis; platelet count; white blood cell count

Mesh:

Substances:

Year:  2020        PMID: 32400905     DOI: 10.1111/odi.13413

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  5 in total

Review 1.  Oxidative Stress and Chemoradiation-Induced Oral Mucositis: A Scoping Review of In Vitro, In Vivo and Clinical Studies.

Authors:  Huynh Nguyen; Simran Sangha; Michelle Pan; Dong Ha Shin; Hayoung Park; Ali I Mohammed; Nicola Cirillo
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

2.  Inflammation-targeted cannabidiol-loaded nanomicelles for enhanced oral mucositis treatment.

Authors:  Yingke Liu; Xingying Qi; Yashi Wang; Man Li; Quan Yuan; Zhihe Zhao
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

3.  Protective Effects of Cannabidiol on Chemotherapy-Induced Oral Mucositis via the Nrf2/Keap1/ARE Signaling Pathways.

Authors:  Lin Li; Yaowei Xuan; Biao Zhu; Xing Wang; Xiaoyu Tian; Lisheng Zhao; Yan Wang; Xiaoxia Jiang; Ning Wen
Journal:  Oxid Med Cell Longev       Date:  2022-05-25       Impact factor: 7.310

4.  Cannabinoids in periodontal disease amid the COVID-19 pandemic.

Authors:  Jun Beom Park; Kwang Mook Jung; Daniele Piomelli
Journal:  J Periodontal Implant Sci       Date:  2020-12       Impact factor: 2.614

Review 5.  Cannabidiol (CBD) in Cancer Management.

Authors:  Kylie O'Brien
Journal:  Cancers (Basel)       Date:  2022-02-10       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.